Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent Biopharma ( (AU:RGT) ) just unveiled an update.
Argent BioPharma has disclosed a change in director Gary Hermon’s interests, with the allocation of 500,000 ordinary shares. The shares were previously nil and are now held directly by Hermon as part of his remuneration package.
The new holding arises from the issue of a performance‑linked incentive component rather than a cash transaction. This award aligns the director’s compensation more closely with company performance and further ties board leadership to shareholder outcomes.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent BioPharma Limited is a biotechnology company listed on the ASX. The company operates in the biopharmaceutical sector, focusing on the development and commercialization of drug products and related therapies for healthcare markets.
Average Trading Volume: 195,442
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.03M
Find detailed analytics on RGT stock on TipRanks’ Stock Analysis page.